Vibativ

RSS

Withdrawn

This medicine's authorisation has been withdrawn

telavancin
MedicineHumanWithdrawn

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Vibativ has been withdrawn at the request of the marketing authorisation holder.

български (BG) (634.53 KB - PDF)

Vaata

español (ES) (549.37 KB - PDF)

Vaata

čeština (CS) (617.26 KB - PDF)

Vaata

dansk (DA) (547.17 KB - PDF)

Vaata

Deutsch (DE) (552 KB - PDF)

Vaata

eesti (ET) (546.46 KB - PDF)

Vaata

ελληνικά (EL) (639.48 KB - PDF)

Vaata

français (FR) (550.8 KB - PDF)

Vaata

hrvatski (HR) (1.06 MB - PDF)

Vaata

italiano (IT) (548.98 KB - PDF)

Vaata

latviešu (LV) (616.63 KB - PDF)

Vaata

lietuvių (LT) (577.48 KB - PDF)

Vaata

magyar (HU) (610.46 KB - PDF)

Vaata

Malti (MT) (620.67 KB - PDF)

Vaata

Nederlands (NL) (547.6 KB - PDF)

Vaata

polski (PL) (615.07 KB - PDF)

Vaata

português (PT) (549.16 KB - PDF)

Vaata

română (RO) (576.09 KB - PDF)

Vaata

slovenčina (SK) (617.05 KB - PDF)

Vaata

slovenščina (SL) (568.91 KB - PDF)

Vaata

suomi (FI) (547.15 KB - PDF)

Vaata

svenska (SV) (548.33 KB - PDF)

Vaata

Product information

български (BG) (1.66 MB - PDF)

Vaata

español (ES) (972.49 KB - PDF)

Vaata

čeština (CS) (1.37 MB - PDF)

Vaata

dansk (DA) (998.7 KB - PDF)

Vaata

Deutsch (DE) (1012.89 KB - PDF)

Vaata

eesti (ET) (990.29 KB - PDF)

Vaata

ελληνικά (EL) (1.7 MB - PDF)

Vaata

français (FR) (1.03 MB - PDF)

Vaata

hrvatski (HR) (1014.8 KB - PDF)

Vaata

italiano (IT) (1.03 MB - PDF)

Vaata

latviešu (LV) (1.41 MB - PDF)

Vaata

lietuvių (LT) (1023.66 KB - PDF)

Vaata

magyar (HU) (1.37 MB - PDF)

Vaata

Malti (MT) (1.44 MB - PDF)

Vaata

Nederlands (NL) (1016.54 KB - PDF)

Vaata

polski (PL) (1.45 MB - PDF)

Vaata

português (PT) (1004.82 KB - PDF)

Vaata

română (RO) (1.06 MB - PDF)

Vaata

slovenčina (SK) (1.39 MB - PDF)

Vaata

slovenščina (SL) (1.39 MB - PDF)

Vaata

suomi (FI) (983.01 KB - PDF)

Vaata

svenska (SV) (1002.26 KB - PDF)

Vaata

Íslenska (IS) (985.54 KB - PDF)

Vaata

norsk (NO) (343.48 KB - PDF)

Vaata
Latest procedure affecting product information:IAIN/0031
08/09/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (529.08 KB - PDF)

Vaata

español (ES) (485.69 KB - PDF)

Vaata

čeština (CS) (529.3 KB - PDF)

Vaata

dansk (DA) (485.73 KB - PDF)

Vaata

Deutsch (DE) (484.5 KB - PDF)

Vaata

eesti (ET) (485.88 KB - PDF)

Vaata

ελληνικά (EL) (528.76 KB - PDF)

Vaata

français (FR) (484.57 KB - PDF)

Vaata

hrvatski (HR) (492.6 KB - PDF)

Vaata

italiano (IT) (503.04 KB - PDF)

Vaata

latviešu (LV) (526.53 KB - PDF)

Vaata

lietuvių (LT) (502.59 KB - PDF)

Vaata

magyar (HU) (508.09 KB - PDF)

Vaata

Malti (MT) (522.89 KB - PDF)

Vaata

Nederlands (NL) (485.68 KB - PDF)

Vaata

polski (PL) (523.08 KB - PDF)

Vaata

português (PT) (485.04 KB - PDF)

Vaata

română (RO) (509.16 KB - PDF)

Vaata

slovenčina (SK) (540.33 KB - PDF)

Vaata

slovenščina (SL) (507.44 KB - PDF)

Vaata

suomi (FI) (488.95 KB - PDF)

Vaata

svenska (SV) (485.59 KB - PDF)

Vaata

Íslenska (IS) (484.25 KB - PDF)

Vaata

norsk (NO) (469.96 KB - PDF)

Vaata

български (BG) (700.28 KB - PDF)

Vaata

español (ES) (613.31 KB - PDF)

Vaata

čeština (CS) (1.19 MB - PDF)

Vaata

dansk (DA) (614.54 KB - PDF)

Vaata

Deutsch (DE) (617.65 KB - PDF)

Vaata

eesti (ET) (617.52 KB - PDF)

Vaata

ελληνικά (EL) (697.34 KB - PDF)

Vaata

français (FR) (618.22 KB - PDF)

Vaata

italiano (IT) (619.69 KB - PDF)

Vaata

latviešu (LV) (660.48 KB - PDF)

Vaata

lietuvių (LT) (634.24 KB - PDF)

Vaata

magyar (HU) (647.41 KB - PDF)

Vaata

Malti (MT) (768.5 KB - PDF)

Vaata

Nederlands (NL) (613.46 KB - PDF)

Vaata

polski (PL) (699.38 KB - PDF)

Vaata

português (PT) (625.07 KB - PDF)

Vaata

română (RO) (643.04 KB - PDF)

Vaata

slovenčina (SK) (679.65 KB - PDF)

Vaata

slovenščina (SL) (744.22 KB - PDF)

Vaata

suomi (FI) (606.41 KB - PDF)

Vaata

svenska (SV) (612 KB - PDF)

Vaata

Product details

Name of medicine
Vibativ
Active substance
telavancin
International non-proprietary name (INN) or common name
telavancin
Therapeutic area (MeSH)
  • Pneumonia, Bacterial
  • Cross Infection
Anatomical therapeutic chemical (ATC) code
J01XA03

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA).

Vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Authorisation details

EMA product number
EMEA/H/C/001240
Marketing authorisation holder
Theravance Biopharma Ireland Umited

Connaught House 1
Burlington Road
Fourth Floor
D04 C5Y6
Dublin 4
Ireland

Marketing authorisation issued
02/09/2011
Revision
10

Assessment history

This page was last updated on

Share this page